Praluent (alirocumab) - hypercholesterolemia - renewable Yuan & Sanofi Praluent (alirocumab) standard / impurity reference Praluent (alirocumab) impurity A Praluent (alirocumab) Impurity A Praluent (alirocumab) impurity B Praluent (alirocumab) Impurity B Praluent (alirocumab) impurity C Praluent (alirocumab) Impurity C Praluent (alirocumab) impurity D Praluent (alirocumab) Impurity D Praluent (alirocumab) impurity E Praluent (alirocumab) Impurity E Praluent (alirocumab) impurity F Praluent (alirocumab) Impurity F Praluent ( alirocumab) impurity G Praluent (alirocumab) Impurity G Praluent (alirocumab) impurity H Praluent (alirocumab) Impurity H Praluent (alirocumab) impurity I Praluent (alirocumab) Impurity I Praluent (alirocumab) impurity J Praluent (alirocumab) Impurity J Kang Lisheng specializes in international New Drug substance and its impurities, and provide medical technology development for clients, agency research, custom synthesis of high-tech enterprises and other discrete services, with a complete and scientific quality management system. The provided COA, H-NMR, MS, HPLC For more product information, please call Miss Zeng 15,989,551,854 or online advice QQ2786277377